Redmile Group Reports 9.9% Stake in Nurix Therapeutics Following Internal Reorganization

Redmile Group, LLC, and its principal Jeremy C. Green, filed an amended Schedule 13G on April 24, 2026, reporting a 9.9% beneficial ownership stake in Nurix Therapeutics, Inc. (NRIX). The filing details a total of 10,696,314 shares of common stock, which includes 7,031,908 shares held directly and 3,664,406 shares issuable upon the exercise of pre-funded warrants, subject to a 9.99% beneficial ownership blocker. The filing primarily reflects an internal reorganization effective April 20, 2026. RedCo II Master Fund, L.P. transferred its entire position pro rata and in kind to its subsidiaries, including RedCo II Offshore SPV LLC. Consequently, RedCo II Master Fund, L.P. exited its position (reporting 0 shares), while RedCo II Offshore SPV LLC emerged as a significant holder with 5,967,424 shares (5.6%). This internal restructuring resulted in no change to the aggregate beneficial ownership managed by Redmile Group and Jeremy Green. The filing serves as both an exit filing for the Master Fund and an initial filing for the SPV.